Rodd AL, Ververis K, Karagiannis TC. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors. Lymphoma. 2012;16(2012):1–10.
Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas—an update 2021. Hematol Oncol. 2021;39(S1):46–51.
Kirsch IR, Watanabe R, O’Malley JT, Williamson DW, Scott L, Elco CP, et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7(308):308ra158.
Peterson E, Weed J, Lo Sicco K, Latkowski JA. Cutaneous T cell lymphoma: a difficult diagnosis demystified. Dermatol Clin. 2019;37(4):455–69.
Weed J, Girardi M. The difficult–and often delayed–diagnosis of CTCL. Sci Transl Med. 2015;7(308):308fs41.
Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome. Arch Dermatol. 2003;139(7).
Lozano A, Duvic M. Cutaneous T-cell lymphoma in non-blood-related family members: report of an additional case. J Am Acad Dermatol. 2007;56(3):521.
Hazen PG, Michel B. Hodgkin’s disease and mycosis fungoides in a married couple. Dermatologica. 1977;154(5):257–60.
Triantafyllopoulou I, Nikolaou V, Marinos L, Papadaki T, Antoniou C. Tumor stage mycosis fungoides in nonblood-related family members. J Am Acad Dermatol. 2014;71(5):1001–2.
Morales-Suárez-Varela MM, Olsen J, Johansen P, Kaerlev L, Guénel P, Arveux P, et al. Occupational sun exposure and mycosis fungoides: a European multicenter case-control study. J Occup Environ Med. 2006;48(4):390–3.
Meibodi N, Ghazvini K, Esmaily H, Hesamifard M, Nahidi Y. Evaluation of the association between epstein-barr virus and mycosis fungoides. Indian J Dermatol. 2015;60(3):321.
Jumbou O, Mollat C, N’Guyen JM, Billaudel S, Litoux P, Dréno B. Increased anti-Epstein-Barr virus antibodies in epidermotropic cutaneous T-cell lymphoma: a study of 64 patients. Br J Dermatol. 1997;136(2):212–6.
Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2003;101(6):2132–6.
Schmidt AN, Robbins JB, Greer JP, Zic JA. Conjugal transformed mycosis fungoides: the unknown role of viral infection and environmental exposures in the development of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;54(5 Suppl):S202–5.
Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996;107(3):373–6.
Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer. 2013;119(4):825–31.
Bobrowicz M, Fassnacht C, Ignatova D, Chang Y, Dimitriou F, Guenova E. Pathogenesis and therapy of primary cutaneous T-cell lymphoma: collegium internationale allergologicum (CIA) upd ate 2020. Int Arch Allergy Immunol. 2020;181(10):733–45.
Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151–65.
da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet. 2015;47(12):1465–70.
Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011–9.
Bastidas Torres AN, Cats D, Mei H, Szuhai K, Willemze R, Vermeer MH, et al. Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes Cancer. 2018;57(12):653–64.
Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood. 2017;130(12):1430–40.
Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291–6.
Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2018;78(6):1068–76.
Moustou A, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol. 2009;61(3):486–504.
Trum NA, Zain J, Abad C, Rosen ST, Querfeld C. Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash. JAAD Case Reports. 2021;14:37–42.
Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol. 2021;35(6):1331–7.
Mahé E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149(1):170–3.
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol. 2004;51(4):660–2.
Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fungoides-associated follicular mucinosis under adalimumab. Br J Dermatol. 2005;153(1):207–8.
Berthelot C, Cather J, Jones D, Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma. 2006;6(4):329–32.
Dauendorffer J, Rivet J, Allard A, Bachelez H. Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br J Dermatol. 2007;156(4):742–3.
Koens L, Senff NJ, Vermeer MH, Ronday HK, Willemze R, Jansen PM. Cutaneous gamma/delta T-cell lymphoma during treatment with etanercept for rheumatoid arthritis. Acta Derm Venereol. 2009;89(6):653–4.
Lafaille P, Bouffard D, Provost N. Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. Arch Dermatol. 2009;145(1):78.
Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29(3):286–97.
Michot C, Costes V, Gerard-Dran D, Guillot B, Combes B, Dereure O. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol. 2009;160(4):889–90.
Bittencourt AL, Oliveira PD, Bittencourt VG, Carvalho EM, Farre L. Adult T-cell leukemia/lymphoma triggered by adalimumab. J Clin Virol. 2013;58(2):494–6.
Papp K, Griffiths C, Gordon K, Lebwohl M, Szapary P, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–54.
Jacks SM, Taylor BR, Rogers RP, Ralston JS, Metcalf JS, Lazarchick J. Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti’) lymphoma after administration of adalimumab. J Am Acad Dermatol. 2014;71(3):e86–7.
Suga H, Sugaya M, Toyama T, Sumida H, Fujita H, Kogure A, et al. A case of mycosis fungoides with large cell transformation associated with infliximab treatment. Acta Derm Venereol. 2014;94(2):233–4.
Ma H, Qiu S, Lu R, Feng P, Lu C. Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma. An Bras Dermatol. 2016;91(3):368–71.
DʼHaens G, Reinisch W, Panaccione R, Satsangi J, Petersson J, Bereswill M, et al. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am J Gastroenterol. 2018 06;113(6):872-82.
Chiba T, Nagai T, Osada SI, Manabe M. Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis. Acta Derm Venereol. 2019;99(9):818–9.
Partarrieu-Mejías F, Díaz-Corpas T, Pérez-Ferriols A, Alegre-de MV. Mycosis fungoides after treatment with tumor necrosis factor-alpha inhibitors for psoriasis: progression or onset. Int J Dermatol. 2019;58(5):e103–5.
Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, Pontes DS, Silverberg JI, Choi J, Pro B, Pincus LB, Guitart J, Zhou XA. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197–9. https://doi.org/10.1016/j.jaad.2020.03.050. (Epub 2020 Mar 27. PMID: 32229275; PMCID: PMC7302979).
Hollins LC, Wirth P, Fulchiero GJ, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8–11.
Miyashiro D, Vivarelli AG, Gonçalves F, Cury-Martins J, Sanches JA. Progression of mycosis fungoides after treatment with dupilumab: a case report. Dermatol Ther. 2020;33(6):e13880.
Tran J, Morris L, Vu
留言 (0)